- Home
- RAPT vs CUE Comparison
RAPT vs CUE Comparison
Compare RAPT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- CUE
- Stock Information
- Founded
- RAPT 2015
- CUE 2014
- Country
- RAPT United States
- CUE United States
- Employees
- RAPT N/A
- CUE N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- CUE Health Care
- Exchange
- RAPT Nasdaq
- CUE Nasdaq
- Market Cap
- RAPT 65.6M
- CUE 64.4M
- IPO Year
- RAPT 2019
- CUE 2018
- Fundamental
- Price
- RAPT $1.52
- CUE $1.50
- Analyst Decision
- RAPT Hold
- CUE Strong Buy
- Analyst Count
- RAPT 10
- CUE 5
- Target Price
- RAPT $5.00
- CUE $5.00
- AVG Volume (30 Days)
- RAPT 920.1K
- CUE 923.5K
- Earning Date
- RAPT 11-12-2024
- CUE 11-19-2024
- Dividend Yield
- RAPT N/A
- CUE N/A
- EPS Growth
- RAPT N/A
- CUE N/A
- EPS
- RAPT N/A
- CUE N/A
- Revenue
- RAPT N/A
- CUE $8,295,000.00
- Revenue This Year
- RAPT N/A
- CUE $104.81
- Revenue Next Year
- RAPT N/A
- CUE N/A
- P/E Ratio
- RAPT N/A
- CUE N/A
- Revenue Growth
- RAPT N/A
- CUE 363.67
- 52 Week Low
- RAPT $1.25
- CUE $0.45
- 52 Week High
- RAPT $27.35
- CUE $3.25
- Technical
- Relative Strength Index (RSI)
- RAPT 39.12
- CUE 50.94
- Support Level
- RAPT $1.31
- CUE $1.32
- Resistance Level
- RAPT $1.96
- CUE $1.99
- Average True Range (ATR)
- RAPT 0.37
- CUE 0.29
- MACD
- RAPT -0.09
- CUE -0.04
- Stochastic Oscillator
- RAPT 10.67
- CUE 26.58
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.